2025 first_quarter Filing

Issues related to pharmaceutical IP, supply chain, and tariffs.

H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L.119-4); H.Con.Res.14, FY2025 Budget Resolution; FY2025 Budget Reconciliation Process; all bio-pharmaceutical related provisions.

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act), antimicrobial resistance, VICP Program, and PBM reform; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act.

Issues related to tax reform. Inflation Reduction Act of 2022 (P.L.117-169) implementation; issues related to international taxation. Issues related to R&D tax credit.

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.